The rising prevalence of type 2 diabetes and obesity, rising aging populations and lifestyle changes, development of new and improved formulations, such as oral and multi-agonist therapies, and the increasing awareness regarding dual benefits of GLP-1 analogues for glycemic control and weight loss are some of the factors driving the expansion of GLP-1 analogues market
doi: 10.1136/gutjnl-2021-324243 [DOI] [PMC free article] [PubMed] [Google Scholar] 19.Siddiqui MS, Yamada G, Vuppalanchi R, et al
The reason for the lower price: Eli Lilly is cutting out the middlemen (such as telehealth companies and concierge docs), who add hefty markups, and will be selling the drug in vials, rather than the costlier, trickier-to-manufacture preloaded pen form (also known as an autoinjector)
4. 2022 Marso SP, et al
GLP-1 prescription drugs or oral GLP-1 supplements, combined with a healthy lifestyle, remains the more credible option to support weight loss and better long-term wellbeing
[17] Current evidence suggests that if GLP-1-associated gastroparesis occurs, it remains an uncommon complication, though ongoing surveillance continues to refine our understanding of this potential risk